Rivaroxaban Tablet
制剂 FDF · Tablet · 10mg, 15mg, 20mg
制剂 FDFConfidentiality：公开
- INN / Generic Name
- Rivaroxaban Tablet
- Dosage Form
- Tablet
- Strength
- 10mg, 15mg, 20mg
- Therapy Area
- Cardiovascular
- Indication
- Prevention of venous thromboembolism after hip or knee replacement; Treatment of deep vein thrombosis or pulmonary embolism; Stroke prevention in non-valvular atrial fibrillation
- Current Status
- 官方 FDF 授权目录（UB830）
- GMP Certification
- US - FDA; CN - NMPA; EU - EMA
- CEP
- No
- DMF Type
- —
- Stability Data
- —
- BE Required
- Not required / waivable
- Registration Pathway
- 已完成注册（目标市场可转移 / 视市场 DCP·NP）
- MOQ
- 询价
- Lead Time
- 询价
- Price Range
- 询价
Registrable Markets
United StatesChinaEUMalaysiaSingapore
Process / Sequence / Exact Price
- Process Summary
- —
- Exact Price
- —